Use of the cheap and readily available 99m-tc as a radioisotope to perform tumour-specific metabolic diagnosis in patients with cancer.
We aim to develop antigen specific t cells against different muc1 glycoforms by means of differentiating stem cells in an artificial thymus towards dcs and t cells. These dcs will be transduced with ad-muc1 and given to t cells to generate antigen specific t cells that can be cloned.
The project exploits the concept of combining synergistic components and micro-organisms as replacement for antibiotic based growth promoters.
To identify and generate translational kinase biomarkers for non-small cell lung cancer in order to develop innovative medicines and to correlate and predict in-vitro and in-vivo drug effects.
The project deals with the combination of a novel viral vector technology with a proprietary dendritic cell vaccine delivery technology to develop immuno-therapies to treat type 1 diabetes, house dust mite allergy and breast cancer; all major immunity-associated diseases.
In this project, a human in-vitro keloid scar model will be developed that can be used to study keloid scar formation and to test and identify novel therapeutics against excessive scar formation.